NCT07553936 Sustainable and Inclusive Use of Alternative Proteins in Mediterranean Supply Chains (CIPROMED)
| NCT ID | NCT07553936 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bologna |
| Condition | Food Preferences |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-03-18 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the effects of foods enriched with alternative protein sources, including edible insects, microalgae, hemp, and legumes, on appetite regulation, satiety, food preferences, and metabolic health in healthy adults and individuals with overweight. The study is part of the CIPROMED project, which aims to support sustainable and circular food systems in the Mediterranean area. The study consists of two phases. In the acute phase, participants will consume different protein-enriched bread products in a controlled setting following a randomized crossover design. Each participant will be exposed to multiple test conditions, allowing within-subject comparisons of postprandial responses. Outcomes assessed during this phase include satiety, hunger, food preference, craving, and short-term energy intake, measured using validated scales and dietary assessment tools. In the chronic phase, participants will follow structured dietary interventions over a longer period within a Mediterranean dietary framework. Participants will be assigned to different dietary patterns including alternative protein-based foods and control products. This phase aims to evaluate the effects of repeated consumption of alternative protein sources on metabolic parameters, gastrointestinal tolerance, nutritional status, and behavioral responses. The study aims to assess the acceptability and physiological effects of alternative protein sources and to compare their impact with that of traditional protein sources commonly used in Mediterranean diets.
Eligibility Criteria
Inclusion Criteria: * Providing signed informed consent, * Being between 18 and 65 years of age, * Having a body mass index (BMI) within the normal range, defined as between 18.5 and 24.9 kg/m² or Having a body mass index (BMI) between 25.0 and 34.9 kg/m², inclusive, corresponding to the overweight category or, at most, class I obesity. Exclusion Criteria: * Positive and documented history of allergy to legumes, insects, microalgae, shellfish, mollusks, crustaceans, snails, insect venom, house dust mites, or any component (ingredient or additive) present in the food prototypes tested, or a confirmed or suspected diagnosis of Celiac Disease. * History of severe allergic reactions to any type of allergen. * Pregnancy or Breastfeeding
Contact & Investigator
Maria Letizia Petroni, Professor
PRINCIPAL INVESTIGATOR
University of Bologna
Frequently Asked Questions
Who can join the NCT07553936 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Food Preferences. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07553936 currently recruiting?
Yes, NCT07553936 is actively recruiting participants. Contact the research team at marialetizia.petroni@unibo.it for enrollment information.
Where is the NCT07553936 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT07553936 clinical trial?
NCT07553936 is sponsored by University of Bologna. The principal investigator is Maria Letizia Petroni, Professor at University of Bologna. The trial plans to enroll 40 participants.